These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31724955)

  • 1. Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study.
    de Lusignan S; Correa A; Dos Santos G; Meyer N; Haguinet F; Webb R; McGee C; Byford R; Yonova I; Pathirannehelage S; Ferreira FM; Jones S
    JMIR Public Health Surveill; 2019 Nov; 5(4):e12016. PubMed ID: 31724955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season.
    de Lusignan S; Damaso S; Ferreira F; Byford R; McGee C; Pathirannehelage S; Shende V; Yonova I; Schmidt A; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2020 Aug; 16(8):1762-1771. PubMed ID: 32118513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons.
    Moeller-Arendt M; van de Witte S; Nauta J; de Voogd H; Rogoll J; Nisslein T
    Vaccine; 2023 Jan; 41(2):606-613. PubMed ID: 36517322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season.
    Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A
    BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme.
    Ranganathan SS; Houghton JE; Davies DP; Routledge PA
    Br J Clin Pharmacol; 2003 Dec; 56(6):658-63. PubMed ID: 14616426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data.
    Trinh L; Macartney K; McIntyre P; Chiu C; Dey A; Menzies R
    Vaccine; 2017 Mar; 35(11):1524-1529. PubMed ID: 28202210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
    Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
    Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.
    Bettinger JA; Rouleau I; Gariepy MC; Bowie WR; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; McNeil SA; McCarthy A; De Serres G;
    Euro Surveill; 2015 Jul; 20(29):21189. PubMed ID: 26227369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audit of the reliability of influenza vaccination and medical information extracted from eHealth records in general practice.
    Regan AK; Gibbs RA; Effler PV
    Vaccine; 2018 May; 36(23):3195-3198. PubMed ID: 29716772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.